CagriSema and the Amylin Pathway: Why Obesity Research Is Looking Beyond GLP-1

Evidence reviewed: 13 September 2026. CagriSema remains investigational in the United States in the sources reviewed for this article. Trial doses below describe research protocols, not treatment instructions.

Abstract

GLP-1 receptor agonists established that appetite regulation could be a powerful therapeutic target. The next question is which additional biological signals can improve treatment. CagriSema combines semaglutide with cagrilintide, a long-acting amylin analogue, bringing together two distinct approaches to controlling food intake.

The interest is timely: Novo Nordisk has submitted the combination for U.S. weight-management approval, reported additional diabetes results in 2026, and continued its development programme. Its latest quarterly materials place the anticipated U.S. decision in the fourth quarter of 2026; that is a company expectation, not an approval. [1]

This review examines amylin receptor biology, the clinical evidence behind CagriSema, and the distinction between a promising mechanism and a proven clinical advantage. The combination has produced substantial weight loss, but its head-to-head trial against tirzepatide also places important limits on claims of superiority.

What Is CagriSema?

CagriSema is an investigational, once-weekly injectable combination of two peptide medicines: cagrilintide and semaglutide. The principal weight-management programme studied a target combination of 2.4 mg of each component. The application submitted in December 2025 was based on the REDEFINE 1 and REDEFINE 2 trials. [2]

Semaglutide activates the GLP-1 receptor. Cagrilintide engages a different receptor family associated with amylin and calcitonin. Calling the combination simply a stronger GLP-1 obscures that distinction: one component adds a separate pharmacological mechanism.

Amylin: Another Signal Involved in Eating

Amylin is a pancreatic hormone released alongside insulin. Its actions help coordinate eating and the arrival of nutrients after a meal. Relevant effects include changes in appetite, food intake and gastric emptying.

Human infusion experiments have examined amylin and GLP-1 separately. In a small crossover study involving people with type 1 diabetes and matched controls, both hormones influenced eating-related responses; the findings also supported GLP-1 effects that did not require endogenous amylin release. This is physiological evidence for distinct, partly overlapping pathways, not a test of long-term CagriSema treatment. [3]

Satiation and Satiety Are Related but Different

Satiation describes the processes that help bring a meal to an end. Satiety describes the suppression of hunger after eating. These terms are often compressed into “appetite suppression,” but they describe different parts of eating behaviour.

That distinction helps frame the therapeutic question. A person may feel full sooner during a meal without experiencing exactly the same change in hunger between meals. A weight-loss percentage cannot, by itself, reveal which aspect of appetite changed.

An Amylin Receptor Is a Protein Partnership

Amylin receptors have an unusual architecture. They form when the calcitonin receptor associates with a receptor activity-modifying protein, or RAMP. RAMP1, RAMP2 and RAMP3 generate the receptor forms commonly called AMY1, AMY2 and AMY3.

Foundational receptor experiments showed that these accessory proteins change the pharmacological behaviour of the calcitonin receptor. The same core receptor protein can therefore recognise and respond to ligands differently depending on its partner. [4]

This matters because “amylin agonist” does not describe a single interchangeable molecular design. Selectivity, receptor distribution and signalling properties can differ between compounds. The clinical performance of one candidate should not be assigned automatically to the entire class.

How Cagrilintide Engages This System

Cagrilintide is often described as an amylin analogue, but its receptor activity is broader: it is a dual amylin and calcitonin receptor agonist. Structural work published in Nature Communications in 2025 examined its binding to all three amylin receptor forms and to the calcitonin receptor.

The researchers found an amylin-like binding arrangement alongside distinctive receptor movements. The molecule also incorporates structural modifications, including a lipid attachment, rather than reproducing the native hormone unchanged. These findings explain why the chemistry and receptor pharmacology deserve attention beyond the drug's name. [5]

Brain Signalling: Strong Mechanistic Evidence, With Limits

A separate 2025 study used mice lacking RAMP1 and RAMP3 to test the contribution of brain amylin receptors. Removing those receptor components impaired cagrilintide's weight-reducing activity. The investigators also measured neuronal activation in regions involved in feeding regulation. [6]

This supports a role for AMY1 and AMY3 in the experimental response. It does not establish the exact contribution of each human brain region or prove that a particular receptor pattern predicts an individual's weight loss. Animal experiments clarify mechanisms; clinical trials establish treatment effects in people.

Why Combine Amylin With GLP-1?

The rationale is to influence food intake through complementary signals. It is not necessary for both components to act at the same receptor for their effects to reinforce each other.

However, plausible complementarity is not the same as demonstrated pharmacological synergy. A combination can outperform either component without proving a mathematically greater-than-additive interaction. That stronger claim requires an appropriate experimental design and analysis.

For readers following Peptimize's research series, this is a useful third example of drug development. Retatrutide explores multiple receptor activities within one molecule. Orforglipron explores nonpeptide oral GLP-1 agonism. CagriSema investigates a combination of two peptide medicines acting through different hormone pathways.

REDEFINE 1: Substantial Weight Loss Without Diabetes

REDEFINE 1 enrolled 3,417 adults without diabetes who had obesity, or overweight with an obesity-related complication. It compared CagriSema, the individual components and placebo over 68 weeks, alongside lifestyle intervention.

The principal treatment-policy analysis estimated a mean weight reduction of 20.4% with CagriSema versus 3.0% with placebo. Gastrointestinal events occurred in 79.6% and 39.9%, respectively, and were predominantly transient and mild to moderate. The peer-reviewed report supports substantial efficacy while also documenting a meaningful tolerability burden. [7]

Why You May Also See a 22.7% Figure

The frequently quoted 22.7% estimate addresses a different question: what the treatment effect would be under an idealised scenario in which participants remained on treatment and did not use other weight-loss therapies. The 20.4% estimate addresses outcomes regardless of treatment discontinuation or other weight-loss treatment. [2]

These are different estimands, not conflicting measurements. Neither is an individual promise. When comparing headlines, match the population, follow-up period and analysis approach before comparing the percentages.

REDEFINE 2: The Type 2 Diabetes Population

REDEFINE 2 studied 1,206 adults with type 2 diabetes and overweight or obesity. At 68 weeks, the estimated mean weight change was −13.7% with CagriSema and −3.4% with placebo. [8]

The smaller average reduction than in REDEFINE 1 illustrates why the population matters. These trials did not randomise people to having or not having diabetes, so their difference cannot be attributed to a single biological cause. Their results should be presented separately.

REDEFINE 4: The Tirzepatide Comparison Matters

In February 2026, Novo Nordisk reported results from an open-label, 84-week trial involving 809 participants. CagriSema did not meet the primary endpoint of demonstrating non-inferiority to tirzepatide.

The treatment-regimen estimates were 20.2% weight loss with CagriSema and 23.6% with tirzepatide. Under the efficacy estimand, the corresponding estimates were 23.0% and 25.5%. These were company-reported headline results. [9]

Failure to establish non-inferiority means the prespecified comparison goal was not met. It should not be rewritten as equivalence, and an attractive mechanism does not override the result. Equally, this finding does not erase the placebo-controlled evidence that CagriSema reduces weight.

REIMAGINE: What the 2026 Diabetes Results Add

The REIMAGINE programme examines glycaemic control in type 2 diabetes. At the June 2026 American Diabetes Association meeting, results were presented from three phase 3 studies.

In REIMAGINE 2, the treatment-regimen analysis reported HbA1c reductions of 1.80 percentage points with CagriSema 2.4 mg/2.4 mg versus 1.68 points with semaglutide 2.4 mg. Weight reductions were 12.9% and 9.2%, respectively. These numbers come from the sponsor's detailed report of the conference results. [10]

The comparison illustrates why statistical significance and clinical magnitude need separate discussion. The additional glucose-lowering effect was smaller numerically than the difference in weight reduction. Weight-management evidence and a future diabetes indication are also separate regulatory questions.

Tolerability Is Part of Efficacy in Practice

A treatment's value depends partly on whether people can continue it. In REDEFINE 1, discontinuation because of adverse events was reported in 5.9% of CagriSema participants versus 3.5% with placebo; the corresponding figures in REDEFINE 2 were 8.4% and 3.0%. [2]

These results should not be interpreted as a reason to endure severe symptoms or as evidence that nausea is required for weight loss. They show why tolerability, treatment persistence and dose exposure must accompany efficacy percentages when a new medicine is evaluated.

Gastric Emptying Is More Than a Side Effect

Studies of pramlintide, another amylin analogue, demonstrated delayed gastric emptying in humans. This provides physiological context for amylin-based treatment, but a short experiment with pramlintide cannot define the duration or magnitude of gastric-emptying effects for CagriSema. [11]

The broader lesson is to distinguish a class mechanism from product-specific evidence. Instructions for another drug should not be repurposed as an unapproved CagriSema dosing or medication-interaction protocol.

Weight Reduction Does Not Answer Every Health Question

Cardiovascular outcomes require direct testing. In SELECT, semaglutide reduced major cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. That result belongs to the studied treatment and population. [12]

It does not establish the magnitude of benefit from adding cagrilintide. Novo Nordisk lists REDEFINE 3, a cardiovascular outcomes study, as ongoing in its 2026 development materials. Improvements in weight or risk factors cannot substitute for the results of that trial. [1]

What Is Useful to Track Today?

Research headlines can prompt useful questions about current prescribed treatment without becoming a reason to switch medicines independently. A concise record can help make a clinical discussion more specific:

• Medication history: prescribed medicine, dates taken and clinician-directed changes.
• Weight trends: repeated measurements under reasonably consistent conditions.
• Appetite patterns: earlier fullness during meals versus hunger between meals.
• Symptoms: timing, severity and whether they interfere with eating, drinking or daily activities.
• Broader progress: measurements and everyday function, rather than the scale alone.

Peptimize supports logging and reviewing personal records. Those records provide context; they do not diagnose a mechanism, predict response to CagriSema or determine which treatment someone should receive.

What to Watch Next

The next questions are concrete: the outcome of regulatory review, complete reporting of comparative trials, cardiovascular outcomes, longer-term persistence and how different doses perform. A planned milestone is not a completed result, and any eventual approval would need to be read alongside its actual indication and prescribing information.

CagriSema's scientific contribution is the clinical testing of amylin alongside GLP-1. The evidence already shows that this combination can produce meaningful weight loss. Its place among obesity treatments will depend on the full balance of comparative benefit, tolerability, long-term outcomes and access—not on receptor count alone.

References

1. Novo Nordisk. Second quarter 2026 investor presentation. August 2026. Regulatory milestones and clinical development programme.
2. Novo Nordisk. FDA submission of CagriSema for weight management. December 2025. Sponsor announcement.
3. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? 2010. PMID: 20194711.
4. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. 1999. PMID: 10385705.
5. Cao J, Belousoff MJ, Johnson RM, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications. 2025;16:3389.
6. Carvas AO, Leuthardt A, Kulka P, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine. 2025;118:105836.
7. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393:635–647. doi:10.1056/NEJMoa2502081.
8. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2502082.
9. Novo Nordisk. REDEFINE 4 headline results: primary endpoint not achieved. 23 February 2026. Sponsor announcement.
10. Novo Nordisk. REIMAGINE 1–3 results presented at ADA 2026. 7 June 2026. Sponsor report of conference results.
11. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. 1997. PMID: 9028722.
12. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232.

Medical Disclaimer

This article provides educational information about clinical research and does not provide individual medical advice. CagriSema is investigational in the United States as of the evidence review date above. Research doses are not instructions for use, and online research products should not be treated as equivalent to a regulated medicine used in a clinical trial. Medication selection, changes and management of adverse effects require an appropriately qualified healthcare professional. Peptimize is a personal tracking tool and does not prescribe or recommend treatment.